>>>
>>> WELL,
>>> WELL, FOR 1 MILLION PEOPLE IN THE U.S., LIVE WITH MULTIPLE
GROSSES OR M.S.
UNPREDICTABLE AND SOMETIMES
DISABLING DISEASE THAT DISRUPTS
THE FLOW OF INFORMATION BETWEEN
THE BRAIN AND THE BODY.
THE FDA HAS RECENTLY APPROVED A
NEW TREATMENT OPTION.
DR. JEKYLL AND NICHOLAS FROM
COLUMBUS, OHIO, JOINS US WITH
MORE.
MORE.
MORE. THANK YOU SO MUCH FOR TALKING
WITH ME TODAY.
>> HEY, THANKS FOR HAVING ME
TODAY.
TODAY.
TODAY. I'M EXCITED TO BE HERE AND TALK
ABOUT RELAXING M.S.
AND WORKING WITH MYERS, PAID
CONSULTANT.
CONSULTANT. >> AWESOME.
>> AWESOME. FIRST OFF, WHAT IS MULTIPLE
SCLEROSIS?
SCLEROSIS? >> SO M.S.
IS AN AUTOIMMUNE DISEASE WHERE
OUR OWN IMMUNE SYSTEM, OUR
WHITE BLOOD CELLS ACTUALLY
ATTACK THE CODING ON OUR
NEURONS, AND THE BRAIN AND
SPINAL CORD AND THAT COULD
CODING IS CALLED MY LINE.
AND ONCE AGAIN, DAMAGE AND ONE
AWAY, IT MAKES IT VERY HARD FOR
SIGNALS TO TRAVEL FROM THE BRAIN
TO THE SPINAL CORD AND OUT TO
THE REST OF THE BODY AND SO
THERE'S A NUMBER OF DIFFERENT
NEUROLOGIC SYMPTOMS THAT PEOPLE
WITH M.S.
WITH M.S.
WITH M.S. CAN EXPERIENCE.
CAN EXPERIENCE. >> AND WHAT ARE SOME OF THE KEY
SYMPTOMS AND RISK FACTORS
INVOLVED?
INVOLVED?
INVOLVED? >> SO COMMON SYMPTOMS FOR
THINGS LIKE NUMBNESS, WEAKNESS,
DIFFICULTY WITH WALKING OR
BALANCE, MEMORY DIFFICULTIES,
REALLY LOW ENERGY OR FATIGUE,
AND EVEN BLADDER DYSFUNCTION.
SEE THERE ARE A NUMBER OF RISK
FASTER THAT WE IDENTIFIED THAT
CAN INCREASE THE RISK OF M.S.
THE MOST COMMON ONES ARE
ACTUALLY HAVING LOW LEVELS OF
VITAMIN D, PEOPLE WHO LIVE
FURTHER AWAY FROM THE EQUATOR,
UP UNTIL THE AGE OF 15,
BERKELEY AT A HIGHER RISK.
SO IF YOU LIVE IN THE NORTH AS
COMPARED TO THE SOUTH, AS A
CHILD, HE WOULD HAVE A SLIGHTLY
INCREASED RISK.
INCREASED RISK. AND WE ALSO KNOW THAT PEOPLE
WHO SMOKE CIGARETTES AND PEOPLE
WHO HAVE EVER BEEN INFECTED
WITH EBV, WHICH IS A VIRUS THAT
CAUSES INFECTIOUS MONO ARE AT A
MUCH HIGHER RISK OF DEVELOPING
M.S.
M.S.
M.S. >>
M.S. >> AND WHAT ARE SOME OF THE
TREATMENT OPTIONS?
TREATMENT OPTIONS? >> SO THERE ARE NUMEROUS
DIFFERENT GERMAN OPTIONS.
PRIOR TO THE 1990s, WE DID NOT
HAVE ANY TREATMENTS FOR M.S.
SO IT IS A VERY EXCITING TIME
TO BE IN M.S., WHERE THERE ARE
SO MANY DIFFERENT CHOICES.
AND THEY ALL VARY IN TERMS OF
THE WAY THERE AT MR. SO THERE
ARE ORAL PILLS, THERE ARE SHOTS
AND THEIR ARE I.V.
INFUSIONS.
INFUSIONS. BUT EACH PATIENT ACTUALLY NEEDS
TO DISCUSS WITH THEIR DOCTOR
WHAT THE MOST APPROPRIATE
TREATMENT IS FOR THEM IN TERMS
OF THE BENEFITS AND SAFETY.
>> AND WHAT IS THE NEW
TREATMENT OPTION THAT THE FDA
RECENTLY APPROVED?
RECENTLY APPROVED? >> YES.
>> YES.
>> YES. SO THE NEW TREATMENT OPTION IS
CALLED SYMPOSIA AND IT IS A
ONCE DAILY ORAL PILL FOR M.S.
AND IT IS DIFFERENT THAN SOME
OF OUR OTHER MEDICATIONS
BECAUSE IT DOES NOT REQUIRE A
FIRST DOES OPERATION OR
MODERATE WHEN SOMEBODY TAKES
THEIR FIRST BUILT.
THEY CAN EXLEY TAKE IT ON THEIR
OWN AT HOME.
AND IT DOES NOT REQUIRE ANY
GENETIC TESTING PRIOR TO
STARTING AND IT ALSO FOR MOST
INDIVIDUALS, DOES NOT REQUIRE
AN EYE EXAM BY AN
OPHTHALMOLOGIST.
OPHTHALMOLOGIST. >> IT ACTUALLY WAS SHOWN TO BE
VERY EFFECTIVE IN CLINICAL
TRIALS, SO IT WAS COMPARING
AGAINST ONE OF OUR OTHER
TREATMENTS, A LEADING
INJECTABLE.
INJECTABLE. WE FOUND IN THE CLINICAL TRIALS
THAT ABOUT 76 TO 78% OF
PATIENTS ON ZEPOSIA WERE
ACTUALLY FREE OF NEW RELAPSES
AS COMPARED TO THE LEADING
INJECTABLE.
INJECTABLE. AND THEN WE ACTUALLY SAW
SIGNIFICANT REDUCTIONS IN NEW
LESIONS ON MRI.
AND WE FOUND THAT NINE OUT OF
10 PATIENTS TAKING ZEPOSIA AND
THE LEADING INJECTABLE ACTUALLY
HAD NO WORSENING OF THERE
PHYSICAL
PHYSICAL
PHYSICAL >> SURE.
>> SURE.
>> SURE. ASSAULT NINE OUT OF 10 DID NOT
HAVE DISABILITY PROGRESSION.
>> WOW.
>> WOW.
>> WOW. AND WHAT ARE SOME OF THE
CLINICAL BENEFITS AND SAFETY
RISKS ASSOCIATED WITH THE
TREATMENT?
TREATMENT? >> SURE.
>> SURE.
>> SURE. SO AS I MENTIONED, THERE ARE
SIGNIFICANT CLINICAL BENEFITS
IN TERMS OF REDUCING NEW
RELAPSES IN PREVENTING NEW
LESIONS ON MRI AND REDUCING THE
RISK OF DISABILITY CORRECTION.
BUT IT IS ALSO IMPORTANT TO
BALANCE THAT WITH THE SAFETY
RISK
RISK
RISK >>
RISK >> SO COMMON SIDE EFFECTS THAT
WE CAN SEE WITH THIS MEDICATION
ARE INCREASED RISK OF UPPER
RESPIRATORY TRACT INFECTION,
ELEVATED LIVER AND ENZYMES
SOMETIMES AN INCREASE IN BLOOD
PRESSURE, SOMETIMES BACK PAIN
OR INCREASED FREQUENCY OF
URINATION.
URINATION. AND WE HAVE ALSO SEEN SOME
INDIVIDUALS WHO WHEN THEY STAND
UP, THEY CAN FEEL LIGHTHEADED
OR HAVE A DROP IN THEIR BLOOD
PRESSURE.
PRESSURE.
PRESSURE. THERE ARE ALSO SOME VERY RARE
RISKS WITH THIS MEDICATION.
AND ALL OF THESE SHOULD BE
DISCUSSED WITH THEIR DOCTOR
PRIOR TO STARTING.
>> AND I CAN IMAGINE FOR
SOMEONE THAT IS SUFFERING WITH
THE SYMPTOMS SOMETIMES RISKS
ARE -- IT IS YOU ARE WILLING TO
TAKE THAT TO HAVE THE BENEFITS.
>> THAT IS RIGHT.
>> SO THIS IS A DISEASE THAT,
UNTREATED, WILL GO ON TO DAMAGE
THE BRAIN AND THE SPINAL CORD
AND CAN EVENTUALLY TAKE AWAY
SOMEBODY ABILITY TO WALK OR TO
DO THEIR JOB.
AND SO IT IS REALLY IMPORTANT
TO FIND A TREATMENT THAT
SOMEBODY IS WILLING TO TAKE AND
THEY TOLERATE WELL BECAUSE
BEING ON TREATMENT FOR M.S.
HAS BEEN SHOWN TO SIGNIFICANTLY
IMPROVE QUALITY OF LIFE AND
PREVENT WORSENING OF FUNCTION
OVER TIME, WHICH IS REALLY
IMPORTANT FOR OUR PATIENTS.
>> AND WHERE CAN VIEWERS GO TO
GET MORE INFORMATION?
>> SO WE ALWAYS RECOMMEND
TALKING TO YOUR DOCTOR OR YOUR
NEUROLOGIST WHO TREATS YOUR
AMAZON THAT YOU CAN ALSO CHECK
OUT ZEPOSIA.COM.
OUT ZEPOSIA.COM.